Colchicine causes prenatal cell toxicity and increases tetraploid risk

doi:10.21203/rs.2.13119/v1

Download PDF

Research article

Colchicine causes prenatal cell toxicity and increases tetraploid risk

https://doi.org/10.21203/rs.2.13119/v1

This work is licensed under a CC BY 4.0 License

Journal Publication

published 13 Nov, 2019

Read the published version in BMC Pharmacology and Toxicology →

You are reading this older preprint version

Read the latest preprint version →

Background Colchicine is a clinical medicine used for relief from gout and familial Mediterranean fever. Because of its toxic effects, intravenous injection of colchicine has been banned, but it is still widely administered orally. We assayed the toxic effects of colchicine in cultured primary chorionic villus cells and amniotic fluid cells to interpret its influence on the placenta and foetus. Methods Bright field record and cell count kit 8 were used to value cell viability. Flow cytometer was used to identify cells markers, cell cycle and cell apoptosis. G-banding was used for karyotype analysis for sample genetic and drug effect evaluation. Results Chorionic villus cells and amniotic fluid cells were characterized as mesenchymal cells that share most cell surface markers and have a similar response to colchicine. Colchicine did not induce a decline in cell viability at low concentrations but suppressed cell proliferation by arresting the cell cycle in the G2/M phase and increased the risk of tetraploid generation in a small subset of cases. Conclusions Our study revealed the results of a colchicine-induced toxicity test in prenatal cells and determined the anti-mitotic biologically functional dose and manner of administration that might reduce the risk of tetraploid generation.

Toxicology

Clinical Pharmacology

Pharmacodynamics

Pharmacokinetics

Colchicine

chorionic villus cells

amniotic fluid cells

cell cycle arrest

tetraploid generation

Colchicine is a natural product extracted from the autumn crocus (Colchicum autumnale) plant. Owing to its biological activity, colchicine has been used in medical care for centuries. There are two main medical uses of colchicine: first, colchicine was regarded as an anti-inflammatory agent used in treating familial Mediterranean fever (FMF), Behcet’s disease and gout; second, colchicine was used as a cardioprotective agent to treat acute and recurrent pericarditis and other cardiovascular-associated abnormalities[1]. In 2009, the United States Food and Drug Administration (FDA) approved colchicine for the treatment of gout and FMF. Based on its pharmacological effects, some clinical trials are in progress and, for some, the results have recently been published, such as those on stroke prevention[2] and enhanced graft survival[3], creating new means for treating disease and promoting wide colchicine medicinal usage. Colchicine is one of the oldest drugs still used today.

Side effects of colchicine accompany its medical usage. At recommended doses, 10% of the patients show some gastrointestinal distress syndromes, such as nausea, vomiting, and particularly diarrhoea. With overdose, it is highly toxic, even fatal[4]. Considering the side effects, the FDA withdrew approval for intravenous colchicine and provided guidelines for reducing the recommended dose and for concomitant use of CYP3A4 and P-glycoprotein inhibitors[5], which target the toxic effects caused by pharmacological use of colchicine.

Most toxicological research on colchicine focuses on treating patient but seldomly focuses on pregnant women or their foetuses. Chorionic villus tissue is a constituent of the placenta, and chorionic villus cells (CVCs) are mesenchymal cells derived from the chorionic villus, from which biopsy samples are taken at the end of the first trimester. Amniotic fluid contains foetal membrane cells and foetal cells, and amniotic fluid cells (AFCs) are mesenchymal cells derived from the amniotic fluid and are extracted during the second trimester. Primary cultures of CVCs and AFCs are widely used in prenatal genetic diagnoses. CVCs and AFCs also have with the same biochemical and genetic characteristics as the placenta and foetus, which are in contact with the amniotic fluid. For this study, we used cultured primary chorionic villus cells (CVCs) and amniotic fluid cells (AFCs) to evaluate the toxic effects of colchicine on the placenta and foetus.

Specimens

This study was approved by the Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical University (Approval number: 2017-001). Six pregnant patients signed informed consent and were told that the diagnostic sample would be used for research. Four pregnant women at 18-21 weeks gestation were undergoing amniocentesis, and two at 12 weeks gestation were undergoing chorionic villus sampling. After the cytogenetic diagnoses were completed, the four AFC lines and two CVC lines were used in this study.

Cell culture

The clinical samples were 8ml amniotic fluid or 100g chorionic villus tissue for each patients. For primary culture, amniotic fluid was centrifuged in 300G and chorionic villus tissue was cut into approximately 1 mm² tissue masses. Then, cell precipitates (or the tissue masses) were resuspended in 4 ml amnioMAX-C100 medium (Cat#12558011, Invitrogen Life Technologies, Carlsbad, CA, USA) and seeded into two 25-cm²culture flasks where they were maintained for 7-9 days at 37°C in 5% CO2. Cells were detached by 0.05% trypsin (Cat#25300054, GIBCO, Invitrogen China Limited, Shanghai, China) for subculture. Clinical cytogenetic diagnosis was performed on passage 1. AFCs and CVCs were subcultured in complete MEM medium (Cat#12571071, GIBCO) supplemented with 20% foetal calf serum (Cat#10100, GIBCO) and 100 U/ml of penicillin and streptomycin (Cat#10378016, Invitrogen). Cells from passages 3-5 were used for the toxicity assays of colchicine (Cat# S2284, Selleck Chemicals, Houston, TX, USA).

G-banding analysis

The P1 subcultured cells were treated with 0.15 μg/ml colchicine for 3 h, detached by 0.05% trypsin, subjected to hypotonic treatment with 0.02% sodium citrate and 2% potassium chloride and fixed in a mixture of methanol and acetic acid in 3:1 (volume to volume). The fix cells were dripped on cold slides and stained with Giemsa for metaphase chromosome analysis that was conducted with an Ikaros system (Carl Zeiss AG, Oberkochen, Germany).

Cell viability assay

A total of 5000 cells were counted in each well of 96-well plates, with triplicate sets for each group. After treatment with different drug concentrations at specific time points, the cell viability was assessed using a commercial CCK-8 (Cell Counting Kit-8) assay (Cat#C0039, Beyotime Biotechnology, Shanghai, China).

Cell surface marker assays

The cells were detached by trypsin and stained by the following fluorescence-conjugated antibodies: CD14-APC, CD34-PE, CD45-FITC, CD105-FITC, CD29-PE, CD44-FITC and CD73-APC. The population analysis was conducted on an Attune NxT flow cytometer (Invitrogen).

Cell cycle assay

Drug-treated cells were detached by trypsin and fixed in 70% ethanol overnight. The fixed cells were assayed using a cell cycle and apoptosis analysis kit (Cat#C1052, Beyotime Biotechnology) on a flow cytometer. The fluorescence intensity was used to distinguish different phases of the cell cycle.

Cell apoptosis assay

After drug treatment, the cells were stained with an annexin V-FITC apoptosis detection kit (Cat#C1062M, Beyotime Biotechnology) and counted by a flow cytometer for analysis. The cells in early apoptosis were the annexin V-positive and PI (propidium iodide)-negative cells, and the cells in late apoptosis were the annexin V- and PI-positive cells.

Statistical analysis

The cell viability was expressed as the mean ± SD, and the percentage of the total number of cells in metaphase was expressed in a scatter diagram. The number of diploid and tetraploid cells in each analysis are presented in the table1. The data were statistically analysed by paired Student's t-tests, and a p-value of <0.05 was considered statistically signiﬁcant. A chi-square test was used to compare the proportion of tetraploid cells in the control group and in the drug-treated groups during each metaphase analysis. A p-value of <0.05 was considered statistically signiﬁcant for either group.

Isolation, culture and characteristics of prenatal cells

After the initial culture, cells (amniotic fluid) and tissues (chorionic villus) were maintained in culture medium for 7 days, and spindle-shaped ﬁbroblast-like cells appeared. Then, the cells were fed fresh medium for 3 days during their expansion, and they formed primary colonies with unclear edges (Fig 1. A). The colonies were detached into single cells by trypsin and re-seeded into the culture flask for the subculture. The morphology of the CVCs and AFCs was homogeneous after three generations of subculture (Fig 1. A). The cell surface markers were identified by flow cytometry and then used for the colchicine-induced toxicity study. The CVCs and AFCs were identified as one kind of mesenchymal cell with shared markers: they were positive for CD29, CD44 and CD73 and were negative for CD14, CD34 and CD45, but the CVCs and AFCs had different levels of CD105 expression (Fig 1. B).

Colchicine affects cell viability in a time- and dose-dependent manner

To evaluate the colchicine-induced toxicity in prenatal cells, we recorded the cell morphology and conducted cell viability analysis. The CCK-8 assay was used for the cell viability evaluation. The CVCs and AFCs displayed different sensitivity of colchicine, with the CVCs more easily induced by colchicine treatment to undergo cell death than the AFCs. For the dose-dependence test, the prenatal cells were treated for 3 hours, and there were no significant changes in AFC morphology or cell viability with increasing concentrations of colchicine (from 0 to 2.4 μg/ml), while 1.2 μg/ml and 2.4 μg/ml of colchicine induced significant decline in CVC viability (Fig 2. A, B and C). For the time-dependence test, the prenatal cells were treated with 0.15 μM colchicine, and a significant decline in cell viability was found for both AFCs (after 24 hours) and CVCs (after 12 hours) (Fig 3. A, B and C). Furthermore, we used flow cytometry to determine the colchicine-induced cell death ratio of the AFCs, as determined by cell viability. Although the cell viability did not change after a 3 hour treatment with 0.15 μg/ml colchicine, there was a significant increase in the ratio of double-positive annexin V and propidium iodide (PI) cells compared with the control group. However, there was no significant change between 3 hours and 24 hours of treatment (Fig 3. D).

Colchicine reduces cell proliferation ability

Although there was no viability change in AFCs and CVCs after 3 hours of 0.15 μg/ml colchicine treatment, to determine the comprehensive effect of the treatment, we cultured the prenatal cells without colchicine for 72 hours and assayed cell viability at different time points to determine whether colchicine treatment affected cell proliferation. Compared to the control group, there were no significant differences in the colchicine treatment group at the initial point in terms of cell morphology or cell viability (Fig 4. A and B). The colchicine treatment group did not show cell proliferation following culture, while the control group grew over 72 hours in culture (Fig 4. A). This result prompted us to conclude that colchicine treatment suppressed the cell proliferation ability compared with the control group, as determined by cell viability assay after 12 hours in culture (Fig 4. B).

Colchicine causes cell cycle arrest and induces polyploids

One biological function of colchicine is its inhibition on spindle formation during mitosis; therefore, colchicine was used to treat prenatal cells for cytogenetic diagnosis at a concentration of 0.15 μg/ml for 3 hours. We studied the influence of colchicine on mitosis and cytogenetics by cell cycle analysis and G-banding karyotype analysis. The cell cycle distribution was assessed at 3 hours and 24 hours after 0.15 μg/ml colchicine treatment. There was no change after 3 hours, while the number of G2/M cells increased after 24 hours (Fig 5. A). The G-banding karyotype analysis was performed in 3 hours with 0.15 μg/ml and 0.075 μg/ml colchicine treatment. For the metaphase cell ratio, no differences were found for the 0.075 μg/ml treatment, while the number of cells treated with 0.15 μg/ml increased compared to the number of untreated cells (Fig 5. B). Most of the cells in metaphase were diploid, but there were tetraploid cells in most cell groups (Fig 5. C). By statistical analysis, we determined that there were no differences in the colchicine treatment group compared to the control group, while a significant increase in tetraploid cells was found in one of the AFC groups treated with 0.15 μg/ml colchicine (Table 1).

Pregnant women exhibit specific and substantially different anatomical and physiological characteristics, resulting in the necessity to evaluate drug pharmacokinetics, functional mechanisms and toxic effects comprehensively. On one hand, the drug must benefit the individual; on the other side, attention must be paid to minimize any side effects not only in the mother but also in the foetus[6]. Colchicine is a clinical medicine that has been in continuous use, and epidemiological studies have suggested that clinical colchicine usage is not associated with foetal malformations or miscarriage, but its anti-mitotic properties may cause pre-term birth, short gestational age and low birthweight[7]. In this study, we used primary prenatal cells to evaluate the cell toxicity induced by colchicine and to uncover the cell biology of the colchicine-induced toxicity in the placenta and foetus.

The CVC and AFC models can be used to evaluate drug cell toxicity to the placenta and foetus. Primary cultures of CVCs and AFCs are widely used in prenatal diagnosis, especially as the foundation of cytogenetic determination. The AFCs and CVCs were harvested at different gestational ages and represent different tissues. Chorionic villus tissue was acquired by biopsy of the placenta at 11-12 weeks of gestation, which was an important period of its growth and maturity[8]. The CVCs were acquired from and represent the placenta. Amniotic fluid was extracted at 18-21 weeks gestation, at which time, the primary circulatory system of the foetus is established[9]. The amniotic fluid is the urine of the foetus, being mainly composed of water but also containing foetal faeces and exfoliated cells of the body and amniotic membranes. The acquired AFCs were regarded as foetal cells. In clinical diagnosis, the CVC genetic report reflects the placenta, and analysis of the AFCs was used to diagnose the foetus, especially for mosaicisms[10]. We used clinically obtained CVCs and AFCs to test colchicine-induced toxicity, partly to determine the influence on the placenta and foetus body. The morphology of passaged CVCs and AFCs differed, with CVCs being slender with clear boundaries, and the AFCs being flat; both were homogeneous as determined by bright field observation. The AFCs shared most of their cell surface markers with the CVCs: both were positive for CD29, CD44 and CD73, and both were negative for CD14, CD34 and CD45; however, CD105 was expressed differently in the two cell lines, and long-term culture increased the CD105 ratio[11]. In our study, although AFCs and CVCs showed the same trend in terms of induced cell toxicity, the CVCs were more sensitive to colchicine in terms of cell viability and proliferation, showing more changes than AFCs, which suggests that colchicine affects the placenta much more than the foetus body, findings that are consistent with the epidemiology studies[7].

To precisely interpret the colchicine-induced toxicity of the placenta and foetus, we need a complex biological model and the ability to monitor the system. The micro-environment is complex and includes multiple types of cells and a complicated extracellular matrix that changes quickly, a situation quite different from our cell model. On the other hand, the concentration of colchicine in our study was higher than the peak plasma concentrations[12]; however, despite the low concentrations, the effect over time might be greater, as the exposure to colchicine would be maintained throughout the entire pregnancy.

It is necessary to evaluate colchicine toxicity in the placenta and foetus. Colchicine is the ﬁrst-line therapy for gout and FMF due to its anti-inﬂammatory properties[13]. Three proteins preferentially bind to colchicine: tubulin, CYP3A4 and P-glycoprotein. The anti-mitotic properties of colchicine that accelerate cells proliferation derive from tubulin binding, the metabolism of colchicine depends on CYP3A4 and P-glycoprotein in the liver, and colchicine is excreted via P-glycoprotein in the kidney[14]. Pregnant women lack an adequate response to colchicine because of an increase in hepatic CYP3A4 enzyme activity[15]. The increase in the dose administered to pregnant women could result in side effects in the foetus, as placenta cells express P-glycoprotein as an important transporter for substance exchange between the mother and foetus[16].

Our prenatal cell toxicity data may reflect the influence of colchicine, but it did not completely mimic the toxic reaction in vivo. For clinical cytogenetic diagnosis, 0.15 μg/ml of colchicine was used to arrest rapidly proliferating cells in metaphase[17]. In our study, prenatal cell viability was not affected in 12 hours by 0.15 μg/ml colchicine treatment, but the ratio of late apoptotic cells (annexin V- and PI-double positive cells) was significantly increased; the continuous treatment over 24 hours resulted in a decline in cell viability but not an increase in apoptotic cells. Furthermore, treatment with 0.15 μg/ml of colchicine for 3 hours did not affect cell viability but limited cell proliferation in the continuous cell culture. Another biological phenomenon of colchicine resulted in an increase in the ratio of mitotic tetraploid cells. Although the total number of tetraploids was low and they were not found in all the samples, it is necessary to take notice of the risk for developing genome abnormalities. Based on these findings, we conclude that the biological function of colchicine was arrest of the cell cycle but not induction of cell death.

In summary, we used primary cells derived from chorionic villus and amniotic fluid to assay colchicine-induced toxicity. Colchicine did not induce a decline in cell viability at low concentrations, but chronic exposure triggered suppressed cell proliferation by arresting the cell cycle in the G2/M phase and increased the risk of tetraploid generation. Our study reflects the influence of colchicine-induced toxicity in the placenta and foetus, but additional studies are needed on a more representative biological model that can be precisely monitored for interpretation of the relevant biological mechanisms.

FDA	Food and Drug Administration
CYP	Cytochrome P450 proteins
CVCs	Chorionic villus cells
AFCs	Amniotic fluid cells
CCK-8	Cell Counting Kit-8
CD	Cluster of Differentiation
PI	Propidium iodide
FMF	Familial Mediterranean fever

Ethics approval and consent to participate

This study was approved by the Ethics Committee of The Third Affiliated Hospital of Guangzhou Medical University (Approval number: 2017-001). As there is no direct interaction with the study participants, informed consent was used to notice the diagnostic sample would be used for research.

Consent for publication

Not applicable.

Availability of data and material

Not applicable.

Competing interests

The authors declare that there is no conflict of interest.

Funding

This work was supported by fundings from National Natural Science Foundation of China (81401205 and 31872800), Clinical Innovation Research Program of Guangzhou Regenerative Medicine and Health Guangdong Laboratory (2018GZR0201002) and Guangzhou City Science and Technology Key Topics Project (201803040009 and 201904020025).

Authors' contributions

WD and XS carried out study design; YX, MY, QP and YL performed the experiments; YX and MY did statistical analysis. DW wrote the paper. All authors read and approved the final manuscript.

Acknowledgements

Not applicable.

Gasparyan AY, Ayvazyan L, Yessirkepov M, Kitas GD: Colchicine as an anti-inflammatory and cardioprotective agent. Expert opinion on drug metabolism & toxicology 2015, 11(11):1781-1794.
Khandkar C, Vaidya K, Patel S: Colchicine for Stroke Prevention: A Systematic Review and Meta-analysis. Clinical therapeutics 2019, 41(3):582-590 e583.
Choi MY, Wee YM, Kim YH, Shin S, Yoo SE, Han DJ: Novel colchicine derivatives enhance graft survival after transplantation via suppression of T-cell differentiation and activity. Journal of cellular biochemistry 2019.
Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y: Colchicine poisoning: the dark side of an ancient drug. Clinical toxicology 2010, 48(5):407-414.
Terkeltaub RA, Furst DE, Digiacinto JL, Kook KA, Davis MW: Novel evidence-based colchicine dose-reduction algorithm to predict and prevent colchicine toxicity in the presence of cytochrome P450 3A4/P-glycoprotein inhibitors. Arthritis and rheumatism 2011, 63(8):2226-2237.
Ito S: Mother and Child: Medication Use in Pregnancy and Lactation. Clinical pharmacology and therapeutics 2016, 100(1):8-11.
Indraratna PL, Virk S, Gurram D, Day RO: Use of colchicine in pregnancy: a systematic review and meta-analysis. Rheumatology 2018, 57(2):382-387.
Boss AL, Chamley LW, James JL: Placental formation in early pregnancy: how is the centre of the placenta made? Human reproduction update 2018, 24(6):750-760.
Pardi G, Cetin I: Human fetal growth and organ development: 50 years of discoveries. American journal of obstetrics and gynecology 2006, 194(4):1088-1099.
Grati FR: Chromosomal Mosaicism in Human Feto-Placental Development: Implications for Prenatal Diagnosis. Journal of clinical medicine 2014, 3(3):809-837.
Wang D, Chen R, Zhong X, Fan Y, Lai W, Sun X: Levels of CD105(+) cells increase and cell proliferation decreases during S-phase arrest of amniotic fluid cells in long-term culture. Experimental and therapeutic medicine 2014, 8(5):1604-1610.
Ferron GM, Rochdi M, Jusko WJ, Scherrmann JM: Oral absorption characteristics and pharmacokinetics of colchicine in healthy volunteers after single and multiple doses. Journal of clinical pharmacology 1996, 36(10):874-883.
Roubille F, Kritikou E, Busseuil D, Barrere-Lemaire S, Tardif JC: Colchicine: an old wine in a new bottle? Anti-inflammatory & anti-allergy agents in medicinal chemistry 2013, 12(1):14-23.
Slobodnick A, Shah B, Pillinger MH, Krasnokutsky S: Colchicine: old and new. The American journal of medicine 2015, 128(5):461-470.
Aweeka FT, Hu C, Huang L, Best BM, Stek A, Lizak P, Burchett SK, Read JS, Watts H, Mirochnick M et al: Alteration in cytochrome P450 3A4 activity as measured by a urine cortisol assay in HIV-1-infected pregnant women and relationship to antiretroviral pharmacokinetics. HIV medicine 2015, 16(3):176-183.
Al-Enazy S, Ali S, Albekairi N, El-Tawil M, Rytting E: Placental control of drug delivery. Advanced drug delivery reviews 2017, 116:63-72.
Wang D, Chen R, Kong S, Pan QY, Zheng YH, Qiu WJ, Fan Y, Sun XF: Cytogenic and molecular studies of male infertility in cases of Y chromosome balanced reciprocal translocation. Molecular medicine reports 2017, 16(2):2051-2054.

Table 1. Statistical analysis of diploid and tetraploid cells in the prenatal samples.

	Karyotype	Tetraploid VS. Diploid
	Karyotype	Control	0.075 μM Colchicine (P Value)	0.15 μM Colchicine (P Value)
AFC 1	46, XY	2 VS. 20	0 VS. 15 (>0.05)	0 VS. 19 (>0.05)
AFC 2	46, XX	10 VS. 89	3 VS. 49 (>0.05)	8 VS. 65 (>0.05)
AFC 3	46, XX	0 VS. 15	4 VS. 22 (>0.05)	2 VS. 25 (>0.05)
AFC 4	46, XY	2 VS. 25	3 VS. 29 (>0.05)	10 VS. 19 (0.014)
CVC 1	46, XY	1 VS. 78	3 VS. 87 (>0.05)	0 VS. 90 (>0.05)
CVC 2	46, XX	3 VS. 80	5 VS. 97 (>0.05)	2 VS. 61 (>0.05)

Significant data are in bold.

Download PDF

Journal Publication

published 13 Nov, 2019

Read the published version in BMC Pharmacology and Toxicology →

Editorial decision: Major revision
13 Sep, 2019
Review #1 received at journal
31 Aug, 2019
Reviewer #4 agreed at journal
28 Aug, 2019
Review #3 received at journal
28 Aug, 2019
Reviewer #3 agreed at journal
26 Aug, 2019
Review #2 received at journal
25 Aug, 2019
Reviewer #2 agreed at journal
18 Aug, 2019
Reviewers invited by journal
17 Aug, 2019
Reviewer #1 agreed at journal
17 Aug, 2019
Submission checks completed at journal
15 Aug, 2019
Editor invited by journal
15 Aug, 2019
Editor assigned by journal
22 Jul, 2019
First submitted to journal
19 Jul, 2019

You are reading this older preprint version

Read the latest preprint version →

Colchicine causes prenatal cell toxicity and increases tetraploid risk

Status:

Journal Publication

Version 1

Abstract

Figures

Background

Methods

Results

Discussion

Conclusions

Abbreviations

Declarations

References

Table

Status:

Journal Publication

Version 1